State of Connecticut
Regulation of
Department of Consumer Protection
Concerning
Drug Schedule Updates

Section 1. Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies are amended to read as follows:

Sec. 21a-243-7. Controlled substances in schedule I

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule I:

(a) Any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- (1) Acetylalpha-methylfentanyl;
- (2) Acetylmethadol;
- (3) Allylprodine;
- (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM);
- (5) Alphameprodine;
- (6) Alphamethadol;
- (7) Alpha-methylfentanyl;
- (8) Alphamethylthiofentanyl;
- (9) Benzethidine;
- (10) Betacetylmethadol;
- (11) Beta-hydroxy-fentanyl;
- (12) Beta-hydroxy-3-methylfentanyl;
- (13) Betameprodine;
- (14) Betamethadol;
- (15) Betaprodine;
- (16) Clonitazene;
- (17) Dextromoramide;
- (18) Diampromide;
- (19) Diethylthiambutene;
- (20) Difenoxin;
- (21) Dimenoxadol;
- (22) Dimepheptanol;
- (23) Dimethylthiambutene;
- (24) Dioxaphetyl Butyrate;
- (25) Dipipanone;
- (26) Ethylmethylthiambutene;
- (27) Etonitazene;
- (28) Etoxeridine;
- (29) Furethidine;

(30)Hydroxypethidine;
(31)Ketobemidone;
(32)Levomoramide;
(33)Levophenacylmorphan;
(34)3-methylfentanyl;
(35)3-methylthiofentanyl;
(36)Morpheridine;
(37)Noracymethadol;
(38)Norlevorphanol;
(39)Normethadone;
(40)Norpipanone;
(41)Para-fluorofentanyl;
(42)PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(43)Phenadoxone;
(44)Phenampromide;
(45)Phenomorphan;
(46)Phenoperidine;
(47)Piritramide;
(48)Proheptazine;
(49)Properidine;
(50)Propiram;
(51)Racemoramide;
(52)Thiofentanyl;
(53)Tilidine;
(54)Trimeperidine.

(b) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10)Etorphine, except hydrochloride salts;
(11)Heroin;
(12)Hydromorphinol;
(13)Methyldesorphine;
(14)Methyldihydromorphine;
(15)Morphine methylbromide;
(16)Morphine methylsulfonate;
(17)Morphine-N-oxide;
(18)Myrophine;

(19)Nicocodeine;
(20)Nicomorphine;
(21)Normorphine;
(22)Pholcodine;
(23)Thebacon.

(c) Any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine;
(2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
(3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
(4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
(5) 3,4-M ethylenedioxy-N-ethylamphetamine;
(6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
(7) 3,4-methylenedioxymethamphetamine; or MDMA;
(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
(9) 4-methoxyamphetamine; or PMA;
(10)5-methoxy-3,4-methylenedioxy-amphetamine;
(11)5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);
(12)4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP
(13)3,4-methylenedioxy amphetamine; or MDA;
(14)N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
(15)3,4,5-trimethoxy amphetamine;
(16)benzylpiperazine or BZP;
(17)Bufotenine or Mappine;
(18)Alphaethyltryptamine;
(19)Diethyltryptamine or DET;
(20)Dimethyltryptamine or DMT;
(21)Ibogaine;
(22)Lysergic acid diethylamide;
(23)MDVP (3,4-methylenedioxypyrovalerone);
(24)3,4-methylenedioxy-N-methycathione (methylone)
(25)Mephedrone (4-methylmethcathinone);
(26)Mescaline;
(27)Parahexyl or Synhexyl;
(28)Peyote, meaning all parts of the plants;
(29)1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
(30)N-ethyl-3-piperidyl benzilate;
(31)N-methyl-3-piperidyl benzilate;
(32)Psilocybin;
(33)Psilocyn;
(34)Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product;
(35)Salvia divinorum;

(36)Salvinorin A;
(37)Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
(38)4-Bromo-2,5-dimethoxyphenethylamine;
(39)Pyrrolidine analog of phencyclidine, PCP or PHP;
(40)1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
(41)Thiophene analog of phencyclidine, TPCP or TCP;
(42)Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
(43)Trifluoromethylphenylpiperazine or TFMPP.

(d) Any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
  (1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the federal food, drug and cosmetic act;
  (2) Gamma-butyrolactone;
  (3) Mecloqualone;
  (4) Methaqualone; or
  (5) Zolazepam.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
  (1) Aminorex;
  (2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine);
  (3) 4-Methylaminorex;
  (4) Cathinone;
  (5) Fenethylline;
  (6) Methcathinone;
  (7) N-ethylamphetamine;
  (8) N,N-Dimethylamphetamine.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to:
  (1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);
  (2) 1-butyl-3-(1-naphthoyl)indole (JWH-073);
  (3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
  (4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);
  (5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabi-cyclohexanol CP-47,497 C8 homologue).

(g) Any schedule I controlled substance used for a medical purpose under the supervision of a practitioner that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall

have the same designated schedule for state purposes as that designated under the federal Controlled Substances Act unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the general statutes.

Sec. 21a-243-8. Controlled substances in schedule II

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule II:

(a) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding Apomorphine, Dextrorphan, Nalbuphine, Naloxone, Nal-trexone, and their salts, but including the following: Raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, tincture of opium, codeine, dihydroetorphine, ethylmorphine, etorphine hydrochloride, hydrocodone, hydromorhone, metopon, morphine, oripavine, oxycodone, oxymorphone and thebaine;

(2) any salt, compound,isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;

(3) opium poppy and poppy straw;

(4) coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

(5) concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of opium poppy).

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation, Dextrorphan and Levopropoxyphene excepted:

(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) bulk Dextropropoxyphene (nondosage forms);
(6) Carfentanil;
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) Isomethadone;
(11) Levo-alphacetylmethadol or LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;
(16) Methadone-intermediate,4-cyano-2-dimethylamino-4,4-diphenylbutane;

(17) Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenyl-propane-carboxylic acid;
(18) Pethidine (Meperidine);
(19) Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
(20) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate;
(21) Pethidine-Intermediate-C, 1-methyl 4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil;
(28) Tapentadol.

(c) Unless excepted or placed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(2) any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;
(3) Methylphenidate;
(4) Phenmetrazine and its salts;
(5) Lisdexamfetamine and its salts, isomers and salts of isomers.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital;
(2) Glutethimide;
(3) Pentobarbital;
(4) Phencyclidine; and
(5) Secobarbital.

(e) Hallucinogenic Substances:

(1) Nabilone.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine; Phenylacetone (some trade names or other names); phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;
(2) immediate precursors to phencyclidine (PCP);
    (A) 1-phencylohexylamine;
    (B) 1-piperidinocyclohaxanecarbonitrile (PCC).

(g) Marijuana, (1) including any material, compound, mixture or preparation which contains its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation, and (2) excepting any marijuana product that has been approved by the federal Food and Drug Administration or successor agency to have a medical use and

reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency. Any marijuana product described in subdivision (2) of this subsection shall be included in the same schedule designated by the federal Drug Enforcement Administration or successor agency.

(h) Any schedule II controlled substance used for a medical purpose under the supervision of a practitioner that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designated schedule for state purposes as that designated under the federal Controlled Substances Act unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the general statutes.

Sec. 21a-243-9. Controlled substances in schedule III

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule III:

(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
  (1) Benzphetamine;
  (2) Chlorphentermine;
  (3) Clortermine;
  (4) Phendimetrazine.

(b) Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
  (1) Any compound, mixture or preparation containing: Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;
  (2) Any suppository dosage form containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;
  (3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules, except that the following analgesic products shall not be considered to be controlled substances:

(A) Products containing a ratio of fifteen milligrams of long or intermediate acting barbiturates combined with at least one of the following:
  (i) 188 mg aspirin;
  (ii) 375 mg salicylamide; or
  (iii) 70 mg phenacetin, acetanilid or acetaminophen;

(B) Products containing a ratio of fifteen milligrams of short acting barbiturates combined with at least one of the following:
  (i) 307 mg aspirin;
  (ii) 614 mg salicylamide; or

(iii) 106 mg phenacetin, acetanilid or acetaminophen;

(4) Any compound, mixture or preparation containing equal weights of both tiletamine and zolazepam or any salt thereof and not mixed with other psychoactive substances;

(5) Chlorhexadol;

(6) Embutramide;

(7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product;

(8) Ketamine or any salt thereof;

(9) Lysergic acid;

(10) Lysergic acid amide;

(11) Methyprylon;

(12) Sulfondiethylmethane;

(13) Sulfonethylmethane;

(14) Sulfonmethane.

(c) Buprenorphine.

(d) Nalorphine.

(e) Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:

(1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;

(2) not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(3) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;

(4) not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(6) not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;

(7) not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(8) not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(f) Unless expressly intended for administration through implants to nonhuman species and approved for such use by the Federal Food and Drug Administration, any anabolic

steroid including but not limited to, any of the following, or any isomer, ester, salt or derivative of the following that acts in the same manner on the human body:

(1) 3[beta],17-dihydroxy-5a-androstane;
(2) 3[alpha],17[beta]-dihydroxy-5a-androstane;
(3) 5[alpha]-androstan-3,17-dione;
(4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
(5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
(6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
(7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
(8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione);
(9) 4-androstenedione (androst-4-en-3,17-dione);
(10)5-androstenedione (androst-5-en-3,17-dione;
(11)Boldenone;
(12)Boldione;
(13)Chlorotestosterone;
(14)Clostebol;
(15)Dehydrochlormethyltestosterone;
(16)[Delta]1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]- hydroxy-5[alpha]-androst-1-en-3-one);
(17)desoxymethltestosterone;
(18)Dihydrotesterone;
(19)Drostanolone;
(20)Ethylestrenol;
(21)Fluoxymesterone;
(22)Formebulone;
(23)Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan);
(24)13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;
(25)4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one);
(26)4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3- one);
(27)Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3- one);
(28)Mesterolone;
(29)Methandienone;
(30)Methandranone;
(31)Methandriol;
(32)Methandrostenolone;
(33)Methenolone;
(34)17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane;
(35)17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane;
(36)17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
(37)17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
(38)Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
(39)Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);
(40)Methyltesterone;
(41)Mibolerone;

(42)17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]- hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17- [alpha]-methyl-1-testosterone');
(43)Nandrolone;
(44)19-nor-4,9 (10)-androstadienedione;
(45)19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene);
(46)19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene);
(47)19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene);
(48)19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene);
(49)19-nor-4-androstenedione (estr-4-en-3,17-dione);
(50)19-nor-5-androstenedione (estr-5-en-3,17-dione;
(51)Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one);
(52)Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
(53)Norethandrolone;
(54)Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3- one);
(55)Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
(56)Oxandrolone;
(57)Oxymesterone;
(58)Oxymetholone;
(59)Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one);
(60)Stanolone;
(61)Stanozolol;
(62)Testolactone;
(63)Testosterone;
(64)Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11-trien-3-one);
(65)Trenbolone.

(g) Chorionic gonadotropin[.], except when used for injection or implantation in cattle or any other nonhuman species and when such use is approved by the Food and Drug Administration or successor agency.

(h) Any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of such isomers, and esters:
  (1) Gamma-hydroxy butyric acid if contained in a product for which an application has been approved under section 505 of the federal food, drug and cosmetic act; or
  (2) Gamma-butyrolactone.

(i) Any schedule III controlled substance used for a medical purpose under the supervision of a practitioner that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designated schedule for state purposes as that designated under the federal Controlled Substances Act unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the general statutes.

Sec. 21a-243-10. Controlled substances in schedule IV

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule IV:

(a) Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Camazepam;
(5) Carisoprodol;
(6) Chloral betaine;
(7) Chloral hydrate;
(8) Chlordiazepoxide;
(9) Clobazam;
(10) Clonazepam;
(11) Clorazepate;
(12) Clotiazepam;
(13) Cloxazolam;
(14) Delorazepam;
(15) Diazepam;
(16) Dochloralphenazone;
(17) Estazolam;
(18) Etholorvynol;
(19) Ethinamate;
(20) Ethyl-lofiazepate;
(21) Fludiazepam;
(22) Flunitrazepam;
(23) Flurazepam;
(24) Halazepam;
(25) Haloxazolam;
(26) Ketazolam;
(27) Loprazolam;
(28) Lorazepam;
(29) Lormetazepam;
(30) Mebutamate;
(31) Medazepam;
(32) Meprobamate;
(33) Methohexital;
(34) Methylphenobarbital (mephobarbital);
(35) Midazolam;
(36) Nimetazepam;
(37) Nitrazepam;
(38) Nordiazepam;
(39) Oxazepam;
(40) Oxazolam;
(41) Paraldehyde;
(42) Petrichloral;
(43) Phenobarbital;

(44)Pinazepam;
(45)Prazepam;
(46)Quazepam;
(47)Temazepam;
(48)Tetrazepam;
(49)Triazolam;
(50)Zaleplon;
(51)Zolpidem;
(52)Zopiclone.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Cathine;
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Mazindol;
(6) Mefenorex;
(7) Modafinil;
(8) Pemoline
(9) Phentermine
(10)Pipradol;
(11)Sibutramine;
(12)SPA [(-)dimethylamino-1,2-diphenylethane].

(c) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Fenfluramine.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:
(1) Not more than 1 milligram of Difenoxin and not less than 25 micrograms of Atropine Sulfate per dosage unit;
(2) Dextropropoxyphene.

(e) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
(1) Butorphanol; or
(2) Pentazocine.

(f) Any schedule IV controlled substance used for a medical purpose under the supervision of a practitioner that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall

have the same designated schedule for state purposes as that designated under the federal Controlled Substances Act unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the general statutes.

Sec. 21a-243-11. Controlled substances in schedule V

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in Schedule V:

(a) Any compound, mixture, or preparation containing limited quantities of any of the following controlled drugs, which also contain one or more noncontrolled active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the controlled drug alone:

(1) not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams;

(2) not more than 100 milligrams of dihydrocodeine, or any of its salts, per 100 milliliters or per 100 grams;

(3) not more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100 grams;

(4) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(5) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

(6) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers:

(1) Pyrovalerone

(c) Any schedule V controlled substance used for a medical purpose under the supervision of a practitioner that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designated schedule for state purposes as that designated under the federal Controlled Substances Act unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the general statutes.

Statement of Purpose

This proposed regulation enables the Department of Consumer Protection to respond swiftly to changes made by the federal Food and Drug Administration and Drug Enforcement Agency regarding the designation of scheduled drugs. Drugs are consistently being added and removed from the controlled substances list and it is cumbersome to constantly revise regulations to reflect the state of Connecticut's agreement with the research and public safety assessment of the federal agencies overseeing the approval of such drugs. This regulation update will enable the swift state authorization of new drugs approved on a national scale.